Axsome Therapeutics (AXSM) Recent 52-Week High
b"Axsome Therapeutics (AXSM) stock price hit a 52-week high recently. Axsome Therapeutics (AXSM) announced that the drug AXS-05 phase 3 trial met endpoints. The drug significantly delayed the relapse of agitation symptoms in Alzheimer's disease patients. 66% of patients had improved agitation at two weeks and 86% at five weeks. George Tsilis compares AXSM to BMY, LLY, BIIB, and SAVA."